

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-387

PHARMACOLOGY REVIEW(S)

PHARMACOLOGY/TOXICOLOGY REVIEW AND EVALUATION

NDA NUMBER: 22-387

DATE RECEIVED BY CENTER: 6/30/2008

PRODUCT: Tyvaso™ (treprostinil sodium) Inhalation Solution (0.6 mg/ml)

INTENDED CLINICAL POPULATION: Pulmonary arterial hypertension (PAH) patients with NYHA Class III symptoms **b(4)**

SPONSOR: United Therapeutics Corporation,
Research Triangle Park, NC 27709

REVIEW DIVISION: Division of Cardiovascular and Renal Products

PHARM/TOX REVIEWER: Xavier Joseph

PHARM/TOX SUPERVISOR: Charles A. Resnick

DIVISION DIRECTOR: Norman Stockbridge

PROJECT MANAGER: Dan Brum

**REVIEW AND EVALUATION OF PHARMACOLOGY
AND TOXICOLOGY DATA**

**Xavier Joseph, D.V.M.
March 23, 2009**


ORIGINAL NDA DATED: June 26, 2008
CENTER RECEIPT DATE: June 30, 2008
REVIEWER RECEIPT DATE: July 7, 2008

SPONSOR: United Therapeutics Corporation
One Park Drive
Research Triangle Park, NC 27709

DRUG PRODUCT: Trade name - Tyvaso™ Inhalation Solution

DRUG SUBSTANCE: Generic name – treprostinil sodium
Code names – UT-15, LRX-15 and 15AU81

Chemical Structure



FORMULATION: Tyvaso™ Inhalation Solution contains 0.6 mg treprostinil/ml, sodium chloride, sodium citrate (dihydrate), 1N hydrochloric acid, sodium hydroxide and water for injection. (1N sodium hydroxide is used for adjusting the pH of the product.) The sodium salt of treprostinil, the active ingredient, is formed during the drug product manufacturing procedure. Treprostinil inhalation solution (2.9 ml) is packaged into ampoules. [Remodulin® (treprostinil sodium) Injection, the marketed product, has the same formulation as Tyvaso except for the

b(4)

MODE OF ADMINISTRATION: Tyvaso is administered by oral inhalation using an Optineb-ir ultrasonic, pulsed delivery nebulizer; each pulse of Tyvaso contains 6 µg of treprostinil.

PHARMACOLOGICAL CLASS: Prostacyclin (PGI₂) analogue (vasodilator)

PROPOSED INDICATIONS: For the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III — symptoms.

b(4)

PROPOSED DOSAGE REGIMEN: Treatment should be started with 3 breaths (18 µg of treprostinil) per treatment session given 4 times daily. If 3 breaths are not tolerated, the dose may be reduced to 1 or 2 breaths and later increased to 3 breaths as tolerated. The dosage should be increased to 6 breaths and subsequently to the target maintenance dose of 9 breaths (54 µg of treprostinil) per inhalation session given 4 times daily, as tolerated. The maximum dose studied in clinical trials was 12 breaths (72 µg of treprostinil) per inhalation session.

IND UNDER WHICH CLINICAL TRIALS WERE CONDUCTED: IND 70,362 (for inhalation therapy of PAH patients)

RELATED NDAs: United Therapeutics' NDA 21-272 – Remodulin for the sc treatment of PAH patients, and United Therapeutics' NDA 21-272 SE3 – Remodulin for the iv treatment of PAH patients.

EXECUTIVE SUMMARY

Tyvaso™ (treprostinil sodium for inhalation), a chemically stable tricyclic benzindene analogue of prostacyclin (PGI₂), with potent systemic and pulmonary vasodilatory as well as platelet antiaggregatory effects, is being developed for inhalation treatment of pulmonary arterial hypertension (PAH) patients. An injectable formulation of treprostinil sodium has been approved for marketing (Remodulin®) for the treatment of PAH patients either by continuous subcutaneous (sc) or intravenous (iv) routes. Infusion site pain and reactions, and catheter-related infection or sepsis were reported to be the most common adverse events among patients treated sc or iv with treprostinil. With inhalation therapy, by directly applying the drug at the primary site of manifestation of the condition, the adverse effects associated with sc or iv infusion can be avoided.

I. Recommendations**A. Recommendation on Approvability**

Tyvaso™ is approvable from a nonclinical perspective.

B. Recommendations for Additional Nonclinical Studies

None

C. Recommendations for Labeling

1. Sponsor's proposed text under section 8. USE IN SPECIFIC POPULATION, 8.1. **Pregnancy** presently read as follows:

b(4)

We recommend that the above text be revised to read as follows:

b(4)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.